尼洛替尼剂量优化治疗新诊断慢性期慢性髓性白血病:ENESTxtnd最终结果
ENESTxtnd研究评估新诊断慢性期慢性髓性白血病患者接受尼洛替尼治疗的分子学反应动力学及剂量优化策略的影响。421例患者中,12个月主要分子学反应率为70.8%(95%CI 66.2-75.1%),24个月为81.0%。安全性特征与既往研究一致,心血管事件发生率为4.5%。
要点
- 12个月主要分子学反应率为70.8%(95%CI 66.2-75.1%),24个月为81.0%。
- 因疗效不足剂量递增患者中63.6%(56/88)在24个月达主要分子学反应。
- 因不良事件减量患者中74.3%(55/74)在24个月达主要分子学反应。
核心结论
- 尼洛替尼治疗新诊断慢性期慢性髓性白血病患者12个月主要分子学反应率达70.8%,24个月达81.0%。
- 剂量优化策略(因疗效不足递增、因不良事件减量后重新递增)下部分患者仍可获得主要分子学反应。
- 安全性特征与既往研究一致,心血管事件发生率为4.5%(3/4级3.1%)。
研究设计与样本
- ENESTxtnd研究为评估尼洛替尼分子学反应动力学及剂量优化策略影响的研究,共纳入421例新诊断慢性期慢性髓性白血病患者。
- 方案允许因次优反应或治疗失败将尼洛替尼剂量从300 mg每日两次递增至400 mg每日两次,并允许因不良事件减量后重新递增。
- 研究注册于clinicaltrials.gov(NCT01254188)。
主要发现
- 12个月主要分子学反应(BCR-ABL1≤0.1%国际标准)率为70.8%(95%CI 66.2-75.1%),为主要终点。
- 24个月时81.0%患者达主要分子学反应,其中因疗效不足剂量递增者63.6%(56/88)达主要分子学反应。
- 因不良事件减量者74.3%(55/74)达主要分子学反应,包括重新递增成功的43/54例患者。
- 最常见非血液学不良事件为头痛、皮疹和恶心;心血管事件发生率为4.5%(3/4级3.1%)。
关键数值与推荐
- 主要分子学反应定义为BCR-ABL1≤0.1%(国际标准)。
- 尼洛替尼剂量递增方案:因次优反应或治疗失败从300 mg每日两次增至400 mg每日两次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Extending Molecular Responses (ENESTxtnd) study was conducted to evaluate the kinetics of molecular response to nilotinib in patients with newly diagnosed chronic myeloid leukaemia in chronic phase and the impact of novel dose-optimization strategies on patient outcomes. The ENESTxtnd protocol allowed nilotinib dose escalation (from 300 to 400 mg twice daily) in the case of suboptimal response or treatment failure as well as dose re-escalation for patients with nilotinib dose reductions due to adverse events. Among 421 patients enrolled in ENESTxtnd, 70·8% (95% confidence interval, 66·2-75·1%) achieved major molecular response (BCR-ABL1 ≤ 0·1% on the International Scale) by 12 months (primary endpoint). By 24 months, 81·0% of patients achieved major molecular response, including 63·6% (56 of 88) of those with dose escalations for lack of efficacy and 74·3% (55 of 74) of those with dose reductions due to adverse events (including 43 of 54 patients with successful re-escalation). The safety profile of nilotinib was consistent with prior studies. The most common non-haematological adverse events were headache, rash, and nausea; cardiovascular events were reported in 4·5% of patients (grade 3/4, 3·1%). The study was registered at clinicaltrials.gov (NCT01254188).
引用
- Hughes TP, Munhoz E, Aurelio Salvino M, et al. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol. 2017. PMID: 28699641. doi:10.1111/bjh.14829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。